scholarly journals Prevalence of Respiratory Viral Infections in Children with Asthma in Kermanshah

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Farhad Babaei ◽  
Hamid Reza Mortazavi ◽  
Nasim Kondori ◽  
Bahareh Cheshmenooshi ◽  
Mohsen Moghoofei
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Viral Infections ◽  
Influenza Viruses ◽  
Inflammatory Disorder ◽  
Seasonal Incidence ◽  
Chronic Inflammatory Disorder ◽  
Children With Asthma ◽  
Respiratory Viral Infections ◽  
Syncytial Virus

Background: Asthma is a chronic inflammatory disorder of lung airways, affecting about 300 million people worldwide. Several risk factors are involved in asthma development, such as environmental allergens, genetic susceptibility, and respiratory viral infections. Viral infections induce NF-kB and inflammatory pathways that lead to the production of cytokines, chemokines, and inflammatory proteins and, finally, a reduction of lung volume and function. Objectives: The aim of this study was to evaluate viral infections’ prevalence in children with asthma from 2016 to 2017. Methods: One hundred throat swab samples were collected from asthmatic children. Extraction of RNA and cDNA synthesis were performed to recognize parainfluenza viruses, rhinoviruses, influenza viruses, and respiratory syncytial virus (RSV) using real-time PCR. Also, the associations of age, sex, and other studied factors with asthmatic attacks were evaluated. Results: In this study, 41 viruses were detected, including 21 cases of rhinoviruses (51.22%), 10 cases of parainfluenza (24.39%), seven cases of respiratory syncytial virus (17.07%), and three cases of the influenza virus (7.32%). Regarding seasonal incidence, the prevalence of the viruses was high in autumn and winter, and there was a significant relationship between seasonal incidence and gender. However, there were no statistically significant relationships between the prevalence of the viruses and age or gender. Conclusions: The most important viral causes of childhood asthma in this study were found to be rhinoviruses, followed by parainfluenza. The lowest prevalence was related to the RSV and influenza virus, which the two viruses also showed the lowest seasonal outbreaks. Therefore, it can be said that with an increase in the seasonal incidence of respiratory viruses, the effects of these viruses will be greater on asthma.

scholarly journals DETECTION OF INFLUENZA VIRUS AND PATHOGENS OF ACUTE RESPIRATORY VIRAL INFECTIONS IN POPULATION OF KAZAKHSTAN DURING 2018-2019 EPIDEMIC SEASON

2019 ◽  
Author(s):  
N. G. Klivleyeva ◽  
N. S. Ongarbayeva ◽  
A. M. Baimukhametova ◽  
N. T. Saktaganov ◽  
G. V. Lukmanova ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Influenza A ◽  
Viral Infections ◽  
Influenza Viruses ◽  
Clinical Samples ◽  
Type B ◽  
Epidemic Season ◽  
Parainfluenza Viruses ◽  
Syncytial Virus

Influenza and other acute respiratory viral infections are the most common contemporary infectious diseases resulting in prominent harm to human health and great economic damage. At least five groups of viruses including more than 300 subtypes are currently referred to ARVI pathogens. Such infectious agents are characterized by variability resulting in their altered antigenic characteristics, increased contagiousness, "evasion from immune response and resistance to antivirals. Relevance of influenza and other ARVIs is also accounted for by rapid development of bacteria-associated respiratory diseases. Continuous variability of influenza viruses and emergence of new ARVI pathogens pose a serious threat. In recent years, a simultaneous circulation of subtype A (H1N1) and A (H3N2) influenza viruses with a predominance of a pandemic strain as well as type B viruses have been observed. Among the causative agents of non-influenza ARVIs, respiratory syncytial virus, rhino- and adenoviruses, and I/III parainfluenza viruses are recorded most often. Here we present the data of virology and serological examination of clinical samples collected during the 2018 – 2019 epidemic season in the Republic of Kazakhstan. For this, 2794 clinical samples (2530 nasopharyngeal swabs and 264 blood serums) were collected from patients diagnosed with ARVI, ARI, bronchitis, and pneumonia. Analysis of nasopharyngeal swabs for detection of influenza by RT-PCR demonstrated that mixed etiology influenza viruses with predominance of A/H1N1pdm virus circulated in Kazakhstan. The genetic fingerprints of influenza virus were found in 511 swabs (20.20% of total examined samples). Influenza A virus RNA was detected in 508 biological samples: A/H1N1 – in 289, A/H3N2 – in 209, and unidentified virus subtype in 10 samples. Type B influenza virus was detected in 3 samples. Study of 264 serum samples by HAI assay and ELISA showed emergence of antibodies against influenza A/H1N1, A/H3N2, and B viruses in residents from various regions of Kazakhstan that indirectly confirmed co-circulation of these viruses. 42 influenza virus strains were isolated in chicken embryos, from which 28 were assigned to A/H1N1pdm virus, 13 to A/H3N2 virus, and one isolate was identified as influenza B virus. Laboratory diagnostics of clinical samples for ARVIs established that among identified non-influenza agents respiratory syncytial virus dominated, while rhinoviruses and adenoviruses were less common. Metapneumoviruses, bocaviruses, coronaviruses, and type I parainfluenza viruses were detected in few cases. Comparison of study data with those obtained after examining circulation of influenza viruses during the 2017 – 2018 epidemic season showed that in 2018 – 2019 in Kazakhstan similar to the previous epidemic season, influenza A and B viruses continued to circulate, with prevalence of A/H1N1pdm virus. Identification of non-influenza viruses causing respiratory infections in 2018 – 2019 showed predominance of respiratory syncytial virus, which correlated with data on the 2017 – 2018 epidemic season.

scholarly journals Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus

Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 234
Author(s):  
Sarah Al-Beltagi ◽  
Cristian Alexandru Preda ◽  
Leah V. Goulding ◽  
Joe James ◽  
Juan Pu ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Influenza A Virus ◽  
Broad Spectrum ◽  
Influenza A ◽  
Respiratory Viruses ◽  
Influenza Viruses ◽  
Virus Challenge ◽  
2009 H1n1 ◽  
Syncytial Virus

The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for any disease bears testament to the challenges of antiviral development. We recently showed that non-cytotoxic levels of thapsigargin (TG), an inhibitor of the sarcoplasmic/endoplasmic reticulum (ER) Ca2+ ATPase pump, induces a potent host innate immune antiviral response that blocks influenza A virus replication. Here we show that TG is also highly effective in blocking the replication of respiratory syncytial virus (RSV), common cold coronavirus OC43, SARS-CoV-2 and influenza A virus in immortalized or primary human cells. TG’s antiviral performance was significantly better than remdesivir and ribavirin in their respective inhibition of OC43 and RSV. Notably, TG was just as inhibitory to coronaviruses (OC43 and SARS-CoV-2) and influenza viruses (USSR H1N1 and pdm 2009 H1N1) in separate infections as in co-infections. Post-infection oral gavage of acid-stable TG protected mice against a lethal influenza virus challenge. Together with its ability to inhibit the different viruses before or during active infection, and with an antiviral duration of at least 48 h post-TG exposure, we propose that TG (or its derivatives) is a promising broad-spectrum inhibitor against SARS-CoV-2, OC43, RSV and influenza virus.

scholarly journals Macrolide Therapy in Respiratory Viral Infections

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Jin-Young Min ◽  
Yong Ju Jang
Keyword(s):  
Influenza Virus ◽  
Viral Infection ◽  
Viral Infections ◽  
Wide Spectrum ◽  
Influenza Virus Infection ◽  
Respiratory Viral Infection ◽  
Rsv Infection ◽  
Respiratory Viral Infections ◽  
Syncytial Virus ◽  
Viral Titers

Background. Macrolides have received considerable attention for their anti-inflammatory and immunomodulatory actions beyond the antibacterial effect. These two properties may ensure some efficacy in a wide spectrum of respiratory viral infections. We aimed to summarize the properties of macrolides and their efficacy in a range of respiratory viral infection.Methods. A search of electronic journal articles through PubMed was performed using combinations of the following keywords including macrolides and respiratory viral infection.Results. Bothin vitroandin vivostudies have provided evidence of their efficacy in respiratory viral infections including rhinovirus (RV), respiratory syncytial virus (RSV), and influenza virus. Much data showed that macrolides reduced viral titers of RV ICAM-1, which is the receptor for RV, and RV infection-induced cytokines including IL-1β, IL-6, IL-8, and TNF-α. Macrolides also reduced the release of proinflammatory cytokines which were induced by RSV infection, viral titers, RNA of RSV replication, and the susceptibility to RSV infection partly through the reduced expression of activated RhoA which is an RSV receptor. Similar effects of macrolides on the influenza virus infection and augmentation of the IL-12 by macrolides which is essential in reducing virus yield were revealed.Conclusion. This paper provides an overview on the properties of macrolides and their efficacy in various respiratory diseases.

scholarly journals Influenza virus inhibits respiratory syncytial virus (RSV) infection via a two-wave expression of interferon-induced protein with tetratricopeptide (IFIT) proteins

2020 ◽  
Author(s):  
Yaron Drori ◽  
Jasmine Jacob-Hirsch ◽  
Rakefet Pando ◽  
Aharona Glatman-Freedman ◽  
Nehemya Friedman ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Influenza Infection ◽  
Treatment Strategies ◽  
Respiratory Viruses ◽  
Influenza Viruses ◽  
Rsv Infection ◽  
Syncytial Virus ◽  
Mouse Lungs

AbstractInfluenza viruses and respiratory syncytial virus (RSV) are respiratory viruses that primarily circulate worldwide during the autumn and winter seasons. Seasonal surveillance shows that RSV infection generally precedes influenza. However, in the last four winter seasons (2016-2020) an overlap of the morbidity peaks of both viruses was observed in Israel, and was paralleled by significantly lower RSV infection rates. To investigate whether the influenza virus inhibits RSV we performed coinfection of Human cervical carcinoma (HEp2) cells or mice with influenza and RSV and we observed that the influenza inhibited RSV growth, both in vitro and in vivo. Mass spectrometry analysis of mouse lungs infected with influenza identified a two-wave pattern of protein expression upregulation, which included members of the interferon-induced protein with tetratricopeptide (IFITs) family. Interestingly, in the second peak of upregulation, influenza viruses were no longer detectable in mouse lungs. We also observed that knockdown and overexpression of IFITs in HEp2 cells affected RSV multiplicity. In conclusion, influenza infection inhibits RSV infectivity via upregulation of IFIT proteins in a two-wave modality. Understanding of the interaction between influenza and RSV viruses and immune system involvement will contribute to the development and optimization of future treatment strategies against these viruses.Author SummaryRespiratory syncytial virus (RSV) and influenza viruses are both respiratory viruses associated with morbidity and mortality worldwide. RSV is usually detected in October, with a clear peak in December, whereas influenza virus arrives in November and peaks in January. In the last four seasons, influenza infection overlapped with that of RSV in Israel, which resulted in decreased morbidity of RSV suggesting that influenza virus inhibits RSV infection. To identify the mechanism responsible for the influenza inhibition of RSV we performed experiments in culture and in mice. We observed that influenza infection results in two wave modality of inhibition of RSV infection. Using mass spectrometry perfornmed on lungs from infected mice we show that influenza infection induces the expression of (IFIT) family of proteins which also showed a two-wave modality. Using knockdown and overexpression experiments we showed that indeed the IFTIs inhibits RSV infection. Our study provides new insights on the interaction between influenza and RSV viruses and immune system involvement and contribute to the development of future treatment strategies against these viruses.

scholarly journals PPAR-γ in Macrophages Limits Pulmonary Inflammation and Promotes Host Recovery following Respiratory Viral Infection

2019 ◽  
Vol 93 (9) ◽  
Author(s):  
Su Huang ◽  
Bibo Zhu ◽  
In Su Cheon ◽  
Nick P. Goplen ◽  
Li Jiang ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Alveolar Macrophages ◽  
Viral Infections ◽  
Pulmonary Inflammation ◽  
Type I ◽  
Disease Development ◽  
Host Disease ◽  
Ppar Γ ◽  
Respiratory Viral Infections ◽  
Syncytial Virus

ABSTRACT Alveolar macrophages (AM) play pivotal roles in modulating host defense, pulmonary inflammation, and tissue injury following respiratory viral infections. However, the transcriptional regulation of AM function during respiratory viral infections is still largely undefined. Here we have screened the expression of 84 transcription factors in AM in response to influenza A virus (IAV) infection. We found that the transcription factor PPAR-γ was downregulated following IAV infection in AM through type I interferon (IFN)-dependent signaling. PPAR-γ expression in AM was critical for the suppression of exaggerated antiviral and inflammatory responses of AM following IAV and respiratory syncytial virus (RSV) infections. Myeloid PPAR-γ deficiency resulted in enhanced host morbidity and increased pulmonary inflammation following both IAV and RSV infections, suggesting that macrophage PPAR-γ is vital for restricting severe host disease development. Using approaches to selectively deplete recruiting monocytes, we demonstrate that PPAR-γ expression in resident AM is likely important in regulating host disease development. Furthermore, we show that PPAR-γ was critical for the expression of wound healing genes in AM. As such, myeloid PPAR-γ deficiency resulted in impaired inflammation resolution and defective tissue repair following IAV infection. Our data suggest a critical role of PPAR-γ expression in lung macrophages in the modulation of pulmonary inflammation, the development of acute host diseases, and the proper restoration of tissue homeostasis following respiratory viral infections. IMPORTANCE Respiratory viral infections, like IAV and respiratory syncytial virus (RSV) infections, impose great challenges to public health. Alveolar macrophages (AM) are lung-resident immune cells that play important roles in protecting the host against IAV and RSV infections. However, the underlying molecular mechanisms by which AM modulate host inflammation, disease development, and tissue recovery are not very well understood. Here we identify that PPAR-γ expression in AM is crucial to suppress pulmonary inflammation and diseases and to promote fast host recovery from IAV and RSV infections. Our data suggest that targeting macrophage PPAR-γ may be a promising therapeutic option in the future to suppress acute inflammation and simultaneously promote recovery from severe diseases associated with respiratory viral infections.

scholarly journals CLINICAL-IMMUNOLOGICAL EFFECTIVENESS OF RIBOMUNYL IN CHILDREN WITH VIRUS-INDUCED BRONCHIAL ASTHMA

2020 ◽  
Vol 8 (3) ◽  
pp. 160-168
Author(s):  
E. B. Belan ◽  
E. M. Nikiforova ◽  
T. E. Zayachnikova ◽  
L. N. Shishimorov ◽  
O. V. Magnitskaya
Keyword(s):  
Respiratory Syncytial Virus ◽  
Serum Level ◽  
Bronchial Asthma ◽  
Viral Infections ◽  
Interleukin 4 ◽  
Total Ige ◽  
Basic Therapy ◽  
Ifn Γ ◽  
Respiratory Viral Infections ◽  
Syncytial Virus

The aim of the study is to research the effects of immunostimulant Ribomunyl in virus-induced bronchial asthma (VBA) children.Materials and methods. 14 virus-induced bronchial asthma (VBA) children were agministrated with immunostimulant Ribomunyl as a part of complex therapy in a 18-month trial (3 cycles of treatment). The comparison group consisted of 16 patients who received only standard therapy for bronchial asthma. At the end of the study, against the background of basic BA therapy, the following parameters were estimated: the frequency of acute respiratory viral infections (ARVI), the need for antibacterial therapy, the frequency of IgG to respiratory-syncytial virus (RSV) prevalence, the serum level dynamics of total IgE, IFN-γ, interleukin-4 (IL-4), interferon gamma (IFN-γ).Results. The inclusion of Ribomunyl into the basic therapy complex in virus-induced bronchial asthma (VBA) children, made it possible to reduce the need for the VBA basic therapy complex by 50% and by 12,5% (р=0,0279). At the same time, as for the frequency of acute respiratory viral infections (ARVI), there was a comparable decrease in both groups, but in the main group the number of cases requiring antibiotic therapy decreased from 78.6% to 42.9% (p=0.0199). The inclusion of Ribomunyl into the basic therapy complex resulted in the decrease of the total IgE serum level; in the patients with the initial presence of IgG to the respiratory syncytial virus (RSV), the IL-4 level decreased and the IFN-γ level increased.Conclusion. Ribomunyl improves the treatment of virus-induced bronchial asthma (VBA) children, herewith the dynamics of immunological indicators is more in RSV-seropositive patients.

scholarly journals Differentiating Impacts of Non-Pharmaceutical Interventions on Non-Coronavirus-Disease-2019 Respiratory Viral Infections: Hospital-Based Retrospective Observational Study in Taiwan

2021 ◽  
Author(s):  
Po-Liang Chen ◽  
Isaac Yen-Hao Chu ◽  
Mei-Lin Yeh ◽  
Yin-Yin Chen ◽  
Chia-Lin Lee ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Observational Study ◽  
Pediatric Patients ◽  
Viral Infections ◽  
Respiratory Viruses ◽  
Influenza Viruses ◽  
Retrospective Observational Study ◽  
Enveloped Viruses ◽  
Respiratory Viral Infections ◽  
Pharmaceutical Interventions

Background Physical distancing and facemask use are worldwide recognized as effective non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19). Since January 2020, Taiwan has introduced both NPIs but their effectiveness on non-COVID-19 respiratory viruses (NCRVs) remain underexplored. Methods This retrospective observational study examined electronic records at a tertiary hospital in northern Taiwan from pre-COVID (January–December 2019) to post-COVID period (January–May 2020). Patients with respiratory syndromes were tested for both enveloped (e.g. influenza virus and seasonal coronavirus) and non-enveloped RVs (e.g. enterovirus and rhinovirus) using multiplex reverse-transcription polymerase chain reaction assays. Monthly positivity rates of NCRVs among adult and pediatric patients were analyzed with comparison between pre- and post-COVID periods. Results A total of 9693 patients underwent 12127 multiplex RT-PCR tests. The average positivity rate of NCRVs reduced by 11.2% (25.6% to 14.4%) after nationwide PHIs. Despite the COVID-19 pandemic, the most commonly identified enveloped and non-enveloped viruses were influenza virus and enterovirus/rhinovirus, respectively. Observed reduction in NCRV incidence was predominantly contributed by enveloped NCRVs including influenza viruses. We did not observe epidemiological impacts of NPIs on non-enveloped viruses but an increasing trend in enterovirus/rhinovirus test positivity rate among pediatric patients. Our data were validated using Taiwan’s national notification database. Conclusions Our frontline investigation suggests that the current NPIs in Taiwan might not effectively control the transmission of non-enveloped respiratory viruses, despite their protective effects against influenza and seasonal coronavirus. Hydrogen peroxide or chloride-based disinfectants should be integrated into national preventative strategies against respiratory viral infections in the post-COVID-19 era.

scholarly journals Clinical characteristics and outcomes of adult patients hospitalized with influenza, respiratory syncytial virus and human metapneumovirus infections: a prospective, cohort study

2020 ◽  
Author(s):  
Liang Chen ◽  
Xiudi Han ◽  
Lu Bai ◽  
Jian Zhang
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Disease Severity ◽  
Clinical Features ◽  
Mortality Risk ◽  
Clinical Characteristics ◽  
Viral Infections ◽  
Human Metapneumovirus ◽  
Influenza Like Illness ◽  
Syncytial Virus

Abstract Background Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza virus infections cause countless adult hospitalizations each year, yet the clinical characteristics and outcomes of RSV and hMPV infections in adults remain poorly understood. This study was thus designed to compare the clinical findings and severity between adult patients hospitalized with RSV/hMPV infections relative to those hospitalized with influenza.Methods This study prospectively enrolled 594 patients that had been hospitalized with influenza-like illness and laboratory confirmed RSV, hMPV, or influenza viral infections over the course of three consecutive influenza seasons at a tertiary hospital in China. In order to identify clinical features associated with these three viral infections and with disease severity, univariate and multivariate logistic regression analyses were conducted. Results Myalgia and lymphocyte counts < 0.8×109/L were positively correlated with the incidence of influenza infection, whereas age ≥ 65 years, nasal congestion, dyspnea, and the presence of solid malignant tumors were positively associated with RSV or hMPV infections. However, none of these variables exhibited good predictive performance as a means of discriminating among patients infected with these three different viruses (AUC < 0.70). After controlling for potential confounding variables, RSV infections in pneumonia patients were associated with a comparable 30-day mortality risk [odds ratio (OR) 1.016, 95% confidence interval (CI) 0.267-3.856, p = 0.982], whereas hMPV infection was associated with a reduced risk of mortality (OR 0.144, 95% CI 0.027-0.780, p = 0.025). In patients without pneumonia, however, 30-day mortality risk in patients infected with influenza virus was comparable to that in patients infected with RSV (OR 1.268, 95% CI 0.172-9.355, p = 0.816) or hMPV (OR 1.128, 95% CI 0.122-10.419, p = 0.916). Conclusions Clinical features of influenza, RSV, and hMPV infections are helpful , but not sufficiently distinct to permit discrimination among these three different infection types, and specific pathogenic testing is thus necessary to understand the etiological basis for disease in patients with influenza-like illness. In addition, disease severity associated with these three types of viral infection was inconsistent when comparing patients with and without pneumonia.

Sign in / Sign up

Export Citation Format

Share Document